Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Mallinckrodt
Medtronic
Harvard Business School

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Gossypol

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Gossypol: Sponsors, patents, clinical trial progress

Gossypol is an investigational drug.

There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.

There are seven hundred and fifty-eight US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Gossypol
TitleSponsorPhase
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaNational Cancer Institute (NCI)Phase 1/Phase 2
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaMayo ClinicPhase 1/Phase 2
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI)Phase 1/Phase 2

See all Gossypol clinical trials

Clinical Trial Summary for Gossypol

Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol

See all Gossypol clinical trials

US Patents for Gossypol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gossypol   See Pricing Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA)   See Pricing
Gossypol   See Pricing Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA)   See Pricing
Gossypol   See Pricing Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   See Pricing
Gossypol   See Pricing Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA)   See Pricing
Gossypol   See Pricing Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)   See Pricing
Gossypol   See Pricing Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy University of Georgia Research Foundation Inc. (Athens, GA)   See Pricing
Gossypol   See Pricing Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the sn-2 position COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Acton, AU) GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Barton, AU) NUSEED PTY LTD. (Laverton North, AU)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gossypol

Drugname Country Document Number Estimated Expiration Related US Patent
Gossypol Australia 2014232383 2033-03-15   See Pricing
Gossypol Australia 2019202731 2033-03-15   See Pricing
Gossypol Brazil 112015023267 2033-03-15   See Pricing
Gossypol Canada 2906931 2033-03-15   See Pricing
Gossypol China 105142635 2033-03-15   See Pricing
Gossypol Eurasian Patent Organization 201591607 2033-03-15   See Pricing
Gossypol European Patent Office 2988743 2033-03-15   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Dow
Johnson and Johnson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.